Skip to content

Impact of a Digital Self-Management Program on A1C for Individuals With Type 2 Diabetes

Enhancing Cardiometabolic Care Study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04892680
Enrollment
27
Registered
2021-05-19
Start date
2021-03-04
Completion date
2021-08-02
Last updated
2022-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

type 2 diabetes, diabetes education, digital health, behavior modification

Brief summary

The goal of this study is to evaluate a digital chronic disease self-management program designed to provide virtual support and guidance for patients with type 2 diabetes.

Detailed description

Approximately 45% of patients with type 2 diabetes do not achieve adequate glycemic control (A1C \< 7%). When diabetes is uncontrolled, complications develop that threaten health and endanger life. This study will make an effort to address this growing health challenge and to reduce the burden of diabetes in this population. More broadly, this study will have important implications and benefits for the growing diabetes population in the U.S. Study results will inform future interventions to reduce diabetes and improve outcomes. A better understanding of the efficacy of a digital chronic disease self-management program will directly benefit the participants of the program but, in the future, has the potential to more broadly benefit this population throughout the nation.

Interventions

Digital delivery of a DSMES program designed to build self-management skills and support diabetes management. Recipients have access to online curriculum, a live CDCES, group-based communication forums, and connected technology to track weight, food intake, physical activity and glucose levels.

Sponsors

Sutter Health
CollaboratorOTHER
Palo Alto Medical Foundation
CollaboratorOTHER
Omada Health, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Adults at least 18 years of age and less than 65 years of age * Overweight (BMI ≥ 25 kg/m2, or BMI ≥ 23 kg/m2 if of Asian descent) * Uncontrolled type 2 diabetes (HbA1C ≥7.5% and ≤12%) * Diagnosed with type 2 diabetes at least 6 months ago, but not more than 10 years ago * Has a compatible smartphone running either Android Operating System 5.0 or higher, or iPhone 7 or later, running iOS 11 or higher. * Willing to set up an online account * An email address in regular use * Ambulatory (e.g., living at home and not in a skilled nursing facility) * Able to speak, understand, and read English

Exclusion criteria

* A diagnosis of Type 1 diabetes * Currently pregnant or postpartum (within 4 weeks) * Currently using a continuous glucose monitor to manage diabetes * Known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin * Skin lesions, scarring, redness, infection or edema at the continuous glucose monitor application sites (upper arm) that could interfere with sensor placement or the accuracy of interstitial glucose measurements * An active eating disorder such as anorexia or bulimia (not including binge-eating disorder) for which he/she has received treatment in the past 12 months * Alcohol or substance abuse that impairs ability to participate in the program * Unable to engage in physical activity for more than 2 months over the next 6 months (i.e. due to injury or recent or planned surgery) * Any of the following in the past 3 months AND are not medically cleared by your physician to exercise: Transient ischemic attack or stroke; Heart attack (myocardial infarction); Hospitalization for congestive heart failure; Cardiac surgery (such as coronary artery bypass grafting (CABG), coronary artery stenting); Bariatric/gastric bypass surgery * Received a solid Organ Transplant (kidney, liver, etc.) within the past 6 months * Recent (within the last 6 months) or planned cancer treatment (chemotherapy, radiation, bone marrow transplant, cancer-related surgery - not including hormonal chemotherapy, such as tamoxifen). * On dialysis treatment * Taking steroids or prednisone (high doses) or getting cortisone injection * Stage 4-5 Chronic Kidney Disease * Class 3-4 Congestive Heart Failure * Participation in diabetes education in the last 30 days

Design outcomes

Primary

MeasureTime frameDescription
Change in HbA1c at 6 months from baselineBaseline, 6 monthsNon-fasting venous blood sample

Secondary

MeasureTime frameDescription
Change in weight at 6 months from baselineBaseline, 6 monthsPercentage of body weight loss
Change in medication adherence at 6 months from baselineBaseline, 6 monthsThe Adherence Estimator, a three-item self-report questionnaire, will be used to assess medication adherence

Other

MeasureTime frameDescription
Health care utilization at 6 and 12 months from baselineBaseline, 6 months, 12 monthsPatient electronic health record data will be collected to examine the impact on short-term health care utilization

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026